 
          手机扫码访问本站
 
 
        微信咨询
	
 
	 
	 
						Background: 
					 
						NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. 
					 
						Applications: 
					 
						WB, IHC 
					 
						Name of antibody: 
					 
						RELA (Phospho-Thr505) 
					 
						Immunogen: 
					 
						Synthetic peptide of human RELA (Phospho-Thr505) 
					 
						Full name: 
					 
						v-rel reticuloendotheliosis viral oncogene homolog A (avian) (Phospho-Thr505) 
					 
						Synonyms: 
					 
						p65; NFKB3 
					 
						SwissProt: 
					 
						Q04206 
					 
						IHC positive control: 
					 
						Human breast carcinoma 
					 
						IHC Recommend dilution: 
					 
						50-100 
					 
						WB Predicted band size: 
					 
						65 kDa 
					 
						WB Positive control: 
					 
						HL60 cells treated with TNF-α 
					 
						WB Recommended dilution: 
					 
						500-1000 
					
		
			
				 
			
					 
				
					 
			
				 
			
					 
				
					 
			
				 
			
					 
				
					 
			
				 
			
					 
				
					 
			
				 
			
					 
				
					 
			
				 
			
					 
				
					 
			
				 
			
					 
				
					 
			
				 
			
					 
				
					 
			
				 
			
					 
				
					 
			
				 
			
					 
				
					 
			
				 
			
					 
				
					 
			
				 
		
	
					 
				
					 
			
 
	
 
	